Uwe Primessnig
Overview
Explore the profile of Uwe Primessnig including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
27
Citations
938
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Dang P, Lacour P, Parwani A, Baehr F, Primessnig U, Schoeppenthau D, et al.
J Clin Med
. 2025 Jan;
13(24.
PMID: 39768691
The wearable cardioverter defibrillator (WCD) has emerged as a valuable tool used for temporary protection from sudden cardiac death. However, since the WCD uses surface electrodes to detect arrhythmias, it...
2.
Schrader H, Boldt L, Parwani A, Blaschke F, Wiedenhofer J, Trippel T, et al.
Front Cardiovasc Med
. 2024 Oct;
11:1402137.
PMID: 39399510
Background: Intra-atrial shunts are associated with an elevated risk of embolic stroke of undetermined source (ESUS). Percutaneous occluder implantation is recommended as secondary prevention in younger patients. This study aims...
3.
Primessnig U, Schrader H, Wiedenhofer J, Trippel T, Parwani A, Blaschke F, et al.
Front Cardiovasc Med
. 2024 Aug;
11:1401974.
PMID: 39091357
Background: Percutaneous interventional left atrial appendage occlusion (LAAO) is a reliable, safe, and effective alternative for stroke prevention in selected patients with atrial fibrillation (AF). Methods: In a retrospective observational...
4.
Primessnig U, Wiedenhofer J, Trippel T, Loddenkemper C, Schrader H, Brand A, et al.
Front Cardiovasc Med
. 2024 Jul;
11:1400626.
PMID: 39077114
Introduction: There is a lack of real-world data directly comparing different valve prostheses for transaortic valve replacement (TAVR). We aimed to compare early clinical outcomes at 30-days between the self-expandable...
5.
Alogna A, Berboth L, Faragli A, Otvos J, Lo Muzio F, Di Mauro V, et al.
J Am Coll Cardiol
. 2024 Jan;
83(1):47-59.
PMID: 38171710
Background: The lack of disease-modifying drugs is one of the major unmet needs in patients with heart failure (HF). Peptides are highly selective molecules with the potential to act directly...
6.
Deissler P, Tran K, Falk V, Pieske B, Grubitzsch H, Primessnig U, et al.
Am J Physiol Heart Circ Physiol
. 2023 Aug;
325(4):H729-H738.
PMID: 37594484
Atrial contractility and functional reserve in atrial remodeling (AR) without (AR/-AF) or with atrial fibrillation (AR/+AF) are not well characterized. In this study, functional measurements were performed in right atrial...
7.
Primessnig U, Deissler P, Wakula P, Tran K, Hohendanner F, von Lewinski D, et al.
Front Cardiovasc Med
. 2022 Jul;
9:859014.
PMID: 35865376
Background: Although the angiotensin receptor-neprilysin inhibitor (ARNI) sacubitril/valsartan started a new era in heart failure (HF) treatment, less is known about the tissue-level effects of the drug on the atrial...
8.
Grabowski K, Herlan L, Witten A, Qadri F, Eisenreich A, Lindner D, et al.
Hypertens Res
. 2021 Dec;
45(2):292-307.
PMID: 34916661
Treatment of hypertension-mediated cardiac damage with left ventricular (LV) hypertrophy (LVH) and heart failure remains challenging. To identify novel targets, we performed comparative transcriptome analysis between genetic models derived from...
9.
Wen Y, Deissler P, Primessnig U, Dushe S, Falk V, Parwani A, et al.
Front Cardiovasc Med
. 2021 Nov;
8:739907.
PMID: 34778401
Obesity can influence the structure and function of the atrium, but most studies focused on the relationship of body mass index (BMI) and overt left atrium (LA) dysfunction as assessed...
10.
Hegemann N, Primessnig U, Bode D, Wakula P, Beindorff N, Klopfleisch R, et al.
ESC Heart Fail
. 2021 May;
8(4):3130-3144.
PMID: 34002482
Aims: Heart failure with preserved ejection fraction (HFpEF) is frequently (30%) associated with right ventricular (RV) dysfunction, which increases morbidity and mortality in these patients. Yet cellular mechanisms of RV...